This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruef, J. Articles by Patterson, C. Search for Related Content PubMed PubMed Citation Articles by Ruef, J. Articles by Patterson, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Circulation. 1999;100:659-665.)
© 1999 American Heart Association, Inc.

Basic Science Reports

Flavopiridol Inhibits Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo After Carotid Injury in the Rat

Johannes Ruef, MD; Adam S. Meshel, BS; Zhaoyong Hu, MD; Chris Horaist, MEd; Carol A. Ballinger, PhD; Larry J. Thompson, PhD; Vijay D. Subbarao, MD; Jennifer A. Dumont, PhD; Cam Patterson, MD

From the Division of Cardiology and Sealy Center for Molecular Cardiology, University of Texas Medical Branch, Galveston (J.R., A.S.M., Z.H., C.H., C.A.B., L.J.T., V.D.S., C.P.), and Hoechst Marion Roussel, Inc, Bridgewater, NJ (J.A.D.).

Correspondence to Cam Patterson, MD, University of Texas Medical Branch, Division of Cardiology, 9.138 Medical Research Bldg, 301 University Blvd, Galveston, TX 77555-1064. E-mail cpatters{at}utmb.edu

Background—Smooth muscle cell (SMC) proliferation is a critical component of neointimal formation in many models of vascular injury and in human lesions as well. Cell-cycle inhibition by gene transfer techniques can block SMC proliferation and lesion formation in animal models, although these methods are not yet applicable to the treatment of human disease. Flavopiridol is a recently identified, potent, orally available cyclin-dependent kinase inhibitor.

Methods and Results—Using human aortic SMCs, we found that flavopiridol in concentrations as low as 75 nmol/L resulted in nearly complete inhibition of basic fibroblast growth factor–induced and thrombin-induced proliferation. At this dose, flavopiridol inhibited cyclin-dependent kinase activity, as measured by histone H1 phosphorylation, but had no effect on mitogen-activated protein kinase activation. Induction of the cell cycle–related proteins cyclin D1, proliferating cell nuclear antigen, and phosphorylated retinoblastoma protein was also blocked by flavopiridol. Flavopiridol had no effect on cellular viability. To test whether flavopiridol had a similar activity in vivo when administered orally, we examined neointimal formation in rat carotid arteries after balloon injury. Flavopiridol 5 mg/kg reduced neointimal area by 35% and 39% at 7 and 14 days, respectively, after injury.

Conclusions—Flavopiridol inhibits SMC growth in vitro and in vivo. Its oral availability and selectivity for cyclin-dependent kinases make it a potential therapeutic tool in the treatment of SMC-rich vascular lesions.

Key Words: muscle, smooth • growth substances • angioplasty • carotid arteries

This article has been cited by other articles:

				E. J.W. Wallitt, M. Jevon, and P. I. Hornick Therapeutics of Vein Graft Intimal Hyperplasia: 100 Years On Ann. Thorac. Surg., July 1, 2007; 84(1): 317 - 323. [Abstract] [Full Text] [PDF]

				D. Wang, Z. Liu, Q. Li, M. Karpurapu, V. Kundumani-Sridharan, H. Cao, N. Dronadula, F. Rizvi, A. K. Bajpai, C. Zhang, et al. An Essential Role for gp130 in Neointima Formation Following Arterial Injury Circ. Res., March 30, 2007; 100(6): 807 - 816. [Abstract] [Full Text] [PDF]

				V. Andres Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential Cardiovasc Res, July 1, 2004; 63(1): 11 - 21. [Abstract] [Full Text] [PDF]

				A. M. Taylor and C. A. McNamara Regulation of Vascular Smooth Muscle Cell Growth: Targeting the Final Common Pathway Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1717 - 1720. [Full Text] [PDF]

				V. Sriram and C. Patterson Cell Cycle in Vasculoproliferative Diseases : Potential Interventions and Routes of Delivery Circulation, May 15, 2001; 103(19): 2414 - 2419. [Abstract] [Full Text] [PDF]

				Y. Yamasaki, K. Miyoshi, N. Oda, M. Watanabe, H. Miyake, J. Chan, X. Wang, L. Sun, C. Tang, G. McMahon, et al. Weekly Dosing With the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor SU9518 Significantly Inhibits Arterial Stenosis Circ. Res., March 30, 2001; 88(6): 630 - 636. [Abstract] [Full Text] [PDF]

				J. Ruef, S.-Q. Liu, C. Bode, M. Tocchi, S. Srivastava, M. S. Runge, and A. Bhatnagar Involvement of Aldose Reductase in Vascular Smooth Muscle Cell Growth and Lesion Formation After Arterial Injury Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1745 - 1752. [Abstract] [Full Text] [PDF]